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Abstract
Background: Disassembly of the viral capsid following penetration into the cytoplasm, or uncoating, is a poorly
understood stage of retrovirus infection. Based on previous studies of HIV-1 CA mutants exhibiting altered capsid
stability, we concluded that formation of a capsid of optimal intrinsic stability is crucial for HIV-1 infection.
Results: To further examine the connection between HIV-1 capsid stability and infectivity, we isolated second-site
suppressors of HIV-1 mutants exhibiting unstable (P38A) or hyperstable (E45A) capsids. We identified the respective
suppressor mutations, T216I and R132T, which restored virus replication in a human T cell line and markedly
enhanced the fitness of the original mutants as revealed in single-cycle infection assays. Analysis of the
corresponding purified N-terminal domain CA proteins by NMR spectroscopy demonstrated that the E45A and
R132T mutations induced structural changes that are localized to the regions of the mutations, while the P38A
mutation resulted in changes extending to neighboring regions in space. Unexpectedly, neither suppressor
mutation corrected the intrinsic viral capsid stability defect associated with the respective original mutation.
Nonetheless, the R132T mutation rescued the selective infectivity impairment exhibited by the E45A mutant in
aphidicolin-arrested cells, and the double mutant regained sensitivity to the small molecule inhibitor PF74. The
T216I mutation rescued the impaired ability of the P38A mutant virus to abrogate restriction by TRIMCyp and
TRIM5a.
Conclusions: The second-site suppressor mutations in CA that we have identified rescue virus infection without
correcting the intrinsic capsid stability defects associated with the P38A and E45A mutations. The suppressors also
restored wild type virus function in several cell-based assays. We propose that while proper HIV-1 uncoating in
target cells is dependent on the intrinsic stability of the viral capsid, the effects of stability-altering mutations can
be mitigated by additional mutations that affect interactions with host factors in target cells or the consequences
of these interactions. The ability of mutations at other CA surfaces to compensate for effects at the NTD-NTD
interface further indicates that uncoating in target cells is controlled by multiple intersubunit interfaces in the viral
capsid.
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Background
During retrovirus maturation, the viral capsid protein
(CA) assembles into a shell, referred to as the capsid,
surrounding the viral genomic ribonucleoprotein
(RNP) complex. HIV-1 CA consists of 231 residues
that fold into two distinct domains connected by a
flexible linker. Various surfaces of CA are involved in
HIV-1 capsid formation. Interactions between the N-
terminal domains (NTDs) form hexamers through an
intersubunit NTD-NTD interface, while the C-terminal
domains (CTDs) form dimers that connect adjacent
hexamers through a CTD-CTD interface [1-5]. The
existence of an NTD-CTD interface in the retroviral
capsid was originally inferred from studies of the Rous
sarcoma virus (RSV), in which two lethal MHR muta-
tions in the CTD were rescued by compensatory muta-
tions in the NTD [6]. In HIV-1, NTD-CTD contacts
were detected by hydrogen-deuterium exchange [7]
and chemical cross-linking [8], and in structures of CA
hexamers and pentamers [9,10].
Following cell entry, the HIV-1 particle releases its
core into the host cytoplasm. Subsequently, the core
undergoes an uncoating process, which we define as dis-
assembly or dissociation of the viral capsid from the
internal RNP complex [11]. The details of HIV-1
uncoating, including the timing, location, and mechan-
ism, are poorly understood. HIV-1 preintegration com-
plexes (PICs) isolated from the cytoplasm several hours
after virus entry contain only low levels of CA protein,
suggesting that viral uncoating occurs in the cytoplasm
prior to nuclear entry [12,13]. Reverse transcription
complexes have been isolated at earlier time points, with
some of these complexes retaining low levels of CA [14].
Recent studies employing imaging and pharmacologic
approaches have suggested that uncoating takes place
within a few hours following cell entry, and may be
linked to reverse transcription [15,16].
In a previous study, we observed that mutations in CA
that result in altering the intrinsic stability of the HIV-1
capsid are associated with impaired infectivity [17].
These capsid stability mutants were competent for viral
particle assembly and release and exhibited normal core
morphology by electron microscopy, but most exhibited
defects in reverse transcription in target cells. One of
the mutants, Q63A/Q67A, resulting in unstable capsids
in vitro, was competent for reverse transcription but
impaired for nuclear import [17,18]. Interestingly, PICs
recovered from this mutant contained elevated levels of
CA and were impaired for integration in vitro. Collec-
tively, these studies suggest that uncoating occurs pro-
gressively in the cytoplasm and is required for
productive reverse transcription, nuclear import, and
integration.
Viral determinants besides CA may also be involved in
HIV-1 uncoating. A triple-stranded viral DNA structure
created during reverse transcription was implicated in
uncoating at the nuclear pore. This so-called “DNA
flap” structure was shown to be required for nuclear
import, but not reverse transcription [19]. Mutations in
the HIV-1 matrix protein (MA) can also result in early
postentry defects, suggesting that MA also regulates
uncoating [20-22].
HIV-1 uncoating may also be modulated by host cell
factors. Cellular proteins that may affect uncoating
include cyclophilin A and restrictive alleles of TRIM5a
[23,24]. However, whether these proteins play a direct
role in uncoating remains unknown, owing to a lack of
sensitive and validated cell-based assays to study HIV-1
uncoating in target cells and the difficulty in distinguish-
ing functional from nonfunctional particles [25]. A
recent study also reported that lysates from activated
CD4+ lymphocytes, but not quiescent CD4+ lympho-
cytes, induce disassembly of isolated HIV-1 cores in
vitro, suggesting that HIV-1 uncoating may differ in
activated vs. resting T cells [26].
Amino acids known to affect HIV-1 capsid stability
are located on both domains of the CA protein in vary-
ing locations, suggesting that multiple surfaces of the
CA protein are involved in stabilizing intersubunit con-
tacts. In the present study, we identified second-site
substitutions in CA that restore the ability of HIV-1
mutants containing unstable (P38A) or hyperstable
(E45A) capsids to replicate in T cells. Surprisingly, the
suppressor mutations rescue HIV-1 infectivity without
correcting the intrinsic capsid stability defects associated
with the original mutations.
Results
Second-site suppressor mutations restore replication to
the P38A and E45A mutants
To probe the role of domain interactions in maintaining
optimal HIV-1 capsid stability, second-site suppressor
mutations were isolated by serial passage of P38A and
E45A mutant viruses in human CEM T cells. Virus
supernatants were harvested immediately following the
peak of growth of the mutant virions and were inocu-
lated into fresh cells and the cultures were maintained
until the reemergence of HIV-1 in the cultures. To
determine whether phenotypic reversion was associated
with acquisition of compensatory HIV-1 mutations,
DNA was purified from infected CEM cells harvested
near the peak of growth. Sequence analysis of PCR pro-
ducts from the P38A culture revealed the presence of a
mutation at codon 216 resulting in a substitution of Thr
to Ile (T216I) in addition to the original P38A mutation.
Sequence analysis of PCR products from the E45A
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culture revealed the presence of a mutation at codon
132 resulting in a substitution of Arg to Thr (R132T) in
addition to the original E45A mutation. No other
changes were observed in the PCR-amplified viral
sequences. To determine whether these second-site sub-
stitutions were responsible for the accelerated growth
kinetics of the adapted viruses, the mutations were
transferred into the original P38A and E45A mutant
viral clones. A replication assay was performed with the
resulting double mutant viruses in CEM cells. In con-
trast to the original P38A and E45A mutants, which
failed to replicate in CEM cells within 26 days, the
P38A/T216I and E45A/R132T double mutants both
replicated, though each was delayed relative to the wild
type (Figure 1A, B). These results demonstrate that the
respective second-site mutations, T216I and R132T, par-
tially restore the ability of the corresponding P38A and
E45A mutant viruses to replicate in CEM cells.
Second-site suppressor mutations enhance the infectivity
of the P38A and E45A mutants in a single-cycle assay
Our group previously showed that the P38A and E45A
mutants are impaired at an early post-entry stage of
infection [17]. Therefore, we sought to determine
whether the second-site mutations rescue the P38A and
E45A mutant viruses in a single-round reporter assay.
This assay, which requires expression of Tat from an
integrated provirus, is a useful tool to identify defects in
the early stages of infection. Quantitation of virus infec-
tivity using the HeLa-P4 cell line (HeLa-CD4/LTR-lacZ)
revealed that the T216I and R132T second-site muta-
tions markedly enhanced the infectivity of P38A and
E45A, respectively (Figure 2). We also constructed and
determined the infectivity of the single mutants T216I
and R132T. Both mutants exhibited infectivity similar to
the wild type virus (data not shown). Therefore, the sec-
ond-site mutations function by relieving a defect in a
step of the virus infection cycle prior to integration.
The T216I mutations partially relieves the reverse
transcription impairment exhibited by P38A
Our group previously showed that the P38A and E45A
mutant capsids exhibited altered stability without major
structural defects, and were impaired for reverse tran-
scription, suggesting that the mutations result in aber-
rant uncoating in target cells [17]. Accordingly, the
P38A substitution destabilized the viral capsid, while
E45A resulted in a hyperstable capsid. In follow-up stu-
dies, we have repeatedly observed that the E45A muta-
tion does not impair reverse transcription, but results in
impairment at later stages of infection, after nuclear
entry (Figure 3). In this respect, E45A resembles the
Figure 1 Rescue of P38A (A) and E45A (B) mutants by second-
site mutations T216I and R132T, respectively. Replication of
mutant and wild-type viruses was analyzed in CEM cells. Samples
were collected on the days indicated and analyzed for reverse
transcriptase (RT) activity. Shown are the average values obtained
from duplicate parallel cultures.
Figure 2 Rescue of P38A and E45A infectivity defects
mutations by second-site mutations T216I and R132T. Single-
cycle infectivity was assayed in HeLa-P4 target cells. Infectivity was
determined as the number of infected cells per ng of p24 in the
inoculum, and values are expressed as percentage of wild-type HIV-
1 infectivity. Results shown are the mean values of three
independent experiments, with error bars representing one
standard deviation.
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Q63A/Q67A CA mutant, which exhibits delayed uncoat-
ing in target cells and is impaired for nuclear import
and integration [16,17]. Importantly, the T216I mutation
partially rescued the impaired reverse transcription
exhibited by P38A (Figure 3), consistent with the inter-
pretation that the impaired infectivity exhibited by P38A
is owing to its reduced reverse transcription capacity.
Collectively, these results suggest that a stable capsid is
necessary for efficient reverse transcription in target
cells, while mutants with hyperstable capsids are
impaired at later steps of infection.
Second-site suppressor mutations do not restore normal
capsid stability in vitro
To determine whether the compensatory mutations
restore normal stability to the viral capsid, we isolated
cores from each of the mutant viruses by centrifugation
through a layer of nonionic detergent into a linear
sucrose gradient. We quantified the recovery of core-
associated CA in the fractions corresponding to the viral
cores as a percentage of the total quantity of CA in the
entire gradient. This value was approximately 10% for
wild-type HIV-1 (Figure 4A and 4B). In contrast, the
recovery of CA in P38A cores was about 2%, while that
for E45A cores was approximately 20% (Figure 4B).
Contrary to our expectation, cores recovered from the
double mutants P38A/T216I and E45A/R132T exhibited
CA levels that were similar to those of the correspond-
ing single mutants (Figure 4A and 4B). To further evalu-
ate the relative stability of E45A mutant HIV-1 cores,
Figure 3 Quantitative analysis of reverse transcription of CA
mutants in target cells. HeLa-P4 cells were inoculated with the
indicated HIV-1 mutants, and the second-strand transfer viral DNA
products accumulated at 8 hours were quantified by PCR. In half of
the samples, the reverse transcriptase inhibitor Efavirenz (EFV) was
included as a control for plasmid DNA contamination carryover
from the transfections used to produce the virus stocks. Error bars
represent the standard deviations of triplicate infections, and the
results are representative of three independent experiments.
Figure 4 Second-site suppressor mutations do not restore
capsid stability in vitro. (A and B) Concentrated virions were
subjected to ultracentrifugation through a detergent layer into a
sucrose density gradient. Yields of cores were calculated as the
percentage of the total CA that was detected in the peak fractions
of cores. Results shown are the mean values of three independent
experiments, with error bars representing one standard deviation.
(C) Disassembly of purified HIV-1 cores in vitro. Diluted HIV-1 cores
were incubated at 37°C for the indicated times, followed by
separation of free and core-associated CA by ultracentrifugation.
Supernatants and pellets were analyzed by p24 ELISA. The extent of
disassembly was determined as the percentage of the total CA
protein in the reaction detected in the supernatant. Results shown
are the average values of two independent experiments with
duplicate determinations in each experiment. Error bars represent
the spread of values obtained in the two experiments.
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we assayed the rate of CA dissociation from purified
cores in vitro. The poor recovery of core-associated CA
from the P38A mutant particles precluded its analysis.
Cores isolated from E45A and E45A/R132T both exhib-
ited slower uncoating in vitro relative to wild-type cores
(Figure 4C). Collectively, these results indicate that the
suppressor mutations do not correct the aberrant intrin-
sic stability of the P38A and E45A mutant capsids
observed in vitro.
Suppressor mutations do not restore normal CA assembly
kinetics in vitro
Purified HIV-1 CA protein can assemble into tube-like
structures in a high salt buffer system in vitro [27-30].
The E45A mutation was previously reported to acceler-
ate HIV-1 CA assembly in vitro [31], suggesting that
this mutation enhances protein-protein interactions
between CA subunits. Reasoning that the hyperstability
of the E45A viral capsid may be related to the acceler-
ated CA assembly kinetics in vitro, we asked whether
the suppressor mutations would affect the rate of CA
assembly. Purified recombinant CA proteins encoding
the E45A and E45A/R132T mutations were diluted into
a high salt buffer, and the turbidity of the solution was
monitored spectrophotometrically for 15 minutes fol-
lowing initiation of the reactions. The wild-type CA pro-
teins assembled at a moderate rate, taking nearly 10
minutes for completion. In contrast, the E45A mutant
assembled within 2 minutes (Figure 5A). However, the
accelerated rate of assembly of E45A was not affected
by the suppressor mutation R132T. The P38A and
P38A/T216I mutant proteins also exhibited accelerated
assembly, reaching completion within 3-4 minutes (Fig-
ure 5B). Thus, the effects of the E45A and P38A muta-
tions on CA assembly in vitro were not correlated with
the biological phenotypes of the corresponding CA
mutant viruses.
Structural assessment of mutant CA151 proteins by NMR
1H-15 N HSQC NMR experiments were performed to
assess the effects of the E45A, P38A, E45A/R132T and
R132T mutations on the structure of the N-terminal
domain of CA (CA-NTD). Superpositions of the 1H-15
N HSQC spectra of wild-type and E45A (A), P38A (B),
E45A/R132T (C) and R132T (D) mutants are shown in
Additional file 1. The spectra of all the mutants are very
similar to that of wild type, demonstrating conservation
of the overall global fold. Chemical shift changes due to
the mutations are plotted versus residue number in Fig-
ure 6. Resonance changes caused by the E45A and
R132T mutations when compared with the wild type
spectrum were essentially confined to the mutation
sites. For example, in the E45A mutant only Gly46
(except the mutated residue Glu45) exhibited a large (~
0.8 ppm) chemical shift change. Similarly, only neigh-
boring residues (Ile129, Trp133, and Leu136) were asso-
ciated with noticeable changes, ranging from 0.3 to 1
ppm in the R132T mutant. In contrast, the spectrum of
the P38A mutant exhibited overall smaller changes (<
0.42 ppm), but the mutation affected more residues that
were dispersed over a wider region. For example, eigh-
teen residues exhibit chemical shift changes larger than
the average change plus one standard deviation (SD)
(0.14 ppm). These residues are located around the
mutation site (such as Va36, Ile37 and Met39 on helix
a2), but also in the preceding loop (Lys30-Ser33),
helices a1 (Trp23-Glu28), a3 (Met55) and a7 (L136
and V142). This suggests that a more general effect
such as an overall loosening of the structure may have
occurred. We conclude that the E45A and R132T muta-
tions induce highly localized structural changes,
Figure 5 In vitro capsid assembly analysis. To initiate assembly,
purified recombinant CA proteins were diluted into a buffer,
resulting in a final NaCl concentration of 2.25 M. The turbidity of
the samples was determined with a spectrophotometer at the
indicated times. For reference, the results for the wild type CA
protein are shown in both panels A and B. Values shown are the
average of two parallel determinations. Shown are data from one
representative of 3 independent experiments.
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indicating that the effects of the mutations simply result
from the change in chemical nature of the substituted
amino acid. The small, but more widespread effects of
the P38A mutation on the protein structure suggest that
modulation of structural properties occurs in the
mutant. Thus, the reduced capsid stability of the mutant
may result from subtle changes in the overall structure
and from Pro38’s involvement in the NTD-NTD
Figure 6 Amide chemical shift differences between the wild type and E45A, E45A/R132T and P38A mutant CA-NTD proteins.
Combined 1H, 15 N chemical shift differences between wild-type and mutants E45A (A), E45A/R132T (B) and P38A (C) are plotted versus residue
number. Structural mapping of the chemical shift differences onto the X-ray structure of CA-NTD [1AK4] in ribbon representation is provided in
the inset. The locations of the mutation sites are marked with large green spheres. Positions of residues whose amide resonances exhibit
significant chemical shift differences are color-coded according to the magnitude of the change: red, Δδ > (Δδaverage + 2 × SD); orange, (Δδaverage
+ 2 × SD) > Δδ > (Δδaverage + 1xSD).
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interaction in the assembled capsid. Note that Pro38 is
in close proximity (< 5A) to Thr54, Asn57, and Thr58
of the neighboring CA molecule in the CA hexamer
structure (3H47)[10].
The R132T mutation relieves the cell-cycle dependence of
the E45A mutant
HIV-1 efficiently infects both dividing and nondividing
cells, and the capacity to infect nondividing cells has
been linked genetically to CA [32]. Several mutations in
CA, including E45A, result in selective impairment of
infection of mitotically-arrested cells [25]. We therefore
asked whether introduction of the R132T mutation in
the E45A mutant virus CA would relieve its cell-cycle-
dependence in arrested HeLa cells. Infection by the
E45A mutant was reduced by eight-fold in arrested vs.
control cells, while the wild type and E45A/R132T dou-
ble mutant were only slightly (less than 50%) reduced in
arrested cells. Thus, the R132T second-site substitution
rescued the impaired ability of E45A infection in nondi-
viding cells. In contrast, the P38A and P38A/T216I
mutants behaved similar to wild type HIV-1 and were
only slightly less infectious for arrested vs. dividing cells
(Figure 7). These results indicate that the R132T muta-
tion corrects the selective impairment of infection of
nondividing cells associated with the E45A mutant virus.
Addition of the R132T substitution restores sensitivity of
the E45A mutant to the small molecule inhibitor PF74
In a recent study, we showed that the small molecule
HIV-1 inhibitor PF74 binds and destabilizes the viral
capsid, leading to premature HIV-1 uncoating in target
cells [33]. The E45A substitution rendered HIV-1 resis-
tant to PF74, presumably by stabilizing the capsid, as
the mutation did not reduce PF74 binding to mature
HIV-1 particles. To further probe the effects of the sup-
pressor mutation R132T on the phenotype of the E45A
mutant in target cells, we compared the sensitivity of
wild type, E45A, and E45A/R132T mutant viruses to
inhibition by PF74 in single-cycle infection assays. The
compound was added at various doses to the cells at the
time of virus inoculation, and the number of infected
cells quantified after two days of culture. As previously
shown, the E45A mutant virus exhibited strong resis-
tance to PF74 (Figure 8). By contrast, the E45A/R132T
mutant exhibited nearly wild type sensitivity (IC50 =
0.38 μM vs. 0.26 μM for the wild type virus). The
restored sensitivity of the double mutant virus to PF74
suggests that the R132T mutation partially reverses the
E45A-induced uncoating defect in target cells.
The T216I mutation restores the ability of P38A particles
to saturate TRIM5 host restrictions in monkey cells
The host tripartite motif proteins TRIMCyp and
TRIM5a act as barriers to lentivirus infection by target-
ing the viral capsid in a species-specific manner [34-39].
Restriction of HIV-1 by TRIM5 proteins in simian cells
can be saturated by adding virus-like particles (VLPs) in
trans. In previous work, we showed that the ability of
HIV-1 VLPs to overcome restriction by TRIM5a and
TRIMCyp is reduced by CA mutations that destabilize
the viral capsid [40,41], but not by mutations that ren-
der the capsid hyperstable, leading us to conclude that
Figure 7 Second-site suppressor mutation R132T relieves the
cell-cycle dependence of the E45A mutant in a single-cycle
infectivity assay. Control and aphidicolin-arrested HeLa-P4 cells
were inoculated with the indicated viruses. Infectivity was
determined as described in the legend to Figure 2. Results shown

















Figure 8 Inhibition of wild type, E45A, and E45A/R132T mutant
HIV-1 by PF74. Viruses were added to HeLa-P4 target cells at
predetermined dilutions in the presence of the indicated
concentrations of PF74. Infected cells were identified two days later
by X-gal staining and quantified. Results were expressed as the
extent of infection normalized by the values obtained with the no-
drug controls.
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efficient trans-abrogation of TRIM5 restriction requires
particles with a stable capsid. The ability to abrogate
restriction in trans does not depend on the infectivity of
the decoy particles, as poorly infectious mutants con-
taining hyperstable capsids (e.g. E45A) were competent
in the assay. Our previous results from the assay also
supported the conclusion that HIV-1 CA mutants con-
taining unstable capsids undergo accelerated uncoating
in target cells. Therefore, the dependence of trans-abro-
gation activity on capsid stability provides an informa-
tive probe of capsid disassembly in target cells.
In previous studies, we observed that the P38A muta-
tion impairs the ability of HIV-1 particles to abrogate
host restriction in simian cells owing to capsid instabil-
ity. To test whether the second-site suppressor restores
capsid stability in target cells, we asked whether T216I
restores the ability of P38A particles to abrogate restric-
tion. Owl monkey (OMK) cells, which express TRIM-
Cyp, were inoculated with a fixed quantity of HIV-GFP
reporter virions with various quantities of wild type or
mutant HIV-1 particles (non-GFP-encoding). Titration
of the wild-type particles led to a marked enhancement
of infection by the reporter virus (Figure 9A). By con-
trast, P38A mutant particles were approximately 80%
less effective at abrogating restriction, as we previously
reported [40]. For P38A/T216I mutant particles, the
activity was intermediate between wild type and P38A
levels. In rhesus macaque cells, in which HIV-1 infec-
tion is restricted by TRIM5a, the impaired abrogation
activity of P38A mutant particles was also rescued by
the T216I suppressor mutation (Figure 9B). In both cell
lines, the T216I single mutant exhibited a similar level
of activity as the wild type, demonstrating that the res-
cue of the P38A mutant activity was not due to a gen-
eral enhancement of activity by the suppressor
mutation. Collectively, these results suggest that the
T216I mutation prevents premature disassembly of the
P38A mutant core in target cells, thereby relieving the
impaired ability of the mutant core to interact with
restriction factors.
Discussion
Uncoating, defined as disassembly of the viral capsid in
target cells, is a critical yet poorly understood stage of
retroviral infection. In the present work, we observed
that the R132T and T216I mutations can partially cor-
rect the infectivity defects associated with E45A and
P38A, respectively, without correcting the altered capsid
stability perturbations created by the original mutations.
Similar observations have been reported for RSV, where
second site suppressors of CA mutants failed to correct
aberrant capsid stability [6]. To elucidate the mechan-
isms by which the suppressor mutations rescue the ori-
ginal mutant phenotypes, we examined the kinetics of
CA protein assembly in vitro, and performed target cell-
based assays for viral functions that depend on HIV-1
capsid stability. CA assembly assays did not uncover any
correlation between capsid stability and the mutant phe-
notypes. The cell-based assays, however, were more
revealing. The T216I mutation reversed the impaired
ability of the P38A mutant to abrogate TRIMCyp- and
TRIM5a-mediated restriction of HIV-1. We previously
demonstrated a correlation between efficiency of satura-
tion of restriction and intrinsic capsid stability [40,41];
therefore, the restored ability of P38A/T216I to saturate
CA-specific host restriction likely results from stabiliza-
tion of the viral capsid in the target cells. Furthermore,
the R132T mutation partially rescued the impaired
Figure 9 The second-site mutation T216I restores the ability of
P38A particles to saturate TRIM5 restrictions in simian cells.
Cultures of OMK (A) and FRhK-4 (B) cells were inoculated with the
indicated quantities of VSV-G-pseudotyped CA mutant HIV-1
particles and a fixed subsaturating quantity of GFP-encoding
pseudotyped HIV-1 particles. Results shown are representative of
two independent experiments.
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ability of the E45A mutant to infect nondividing cells,
possibly via reversal of the uncoating defect caused by
the E45A mutation. Similarly, the R132T suppressor
restored sensitivity to PF74, a compound that inhibits
HIV-1 by destabilizing the viral capsid. Collectively,
these data strongly suggest that the E45A uncoating
defect is rescued by the R132T mutation. Apparently,
the putative uncoating defect associated with the P38A
and E45A mutations can be rescued in target cells with-
out restoring normal intrinsic capsid stability.
Although uncoating has not been definitively linked to
the ability of lentiviruses such as HIV-1 to infect nondi-
viding cells, recent studies demonstrate a role of the CA
protein [25,32], and completion of uncoating may be a
requirement for mitosis-independent infection. In accor-
dance with this hypothesis, impaired infection of nondi-
viding cells is associated with CA mutants E45A and
Q63A/Q67A, which exhibit hyperstable capsids and/or
slower uncoating in target cells. Our observation that
R132T rescues the impaired ability of E45A mutant par-
ticles to infect arrested cells confirms that the ability of
lentiviruses to infect nondividing cells is dependent on a
function of the viral capsid, and suggests that this is
linked to the mechanism or timing of uncoating.
Our NMR structural analysis of CA-NTD proteins
suggests that the mutant phenotypes are not a conse-
quence of major structural alterations in the capsid.
NMR structural assessment of the effects of the muta-
tions on the CA-NTD structure revealed no gross con-
formational changes in either P38A or E45A mutants,
nor for the R132T mutant. The P38A substitution, how-
ever, resulted in more extensive changes that could be
related to a general effect of the structural adjustment
for the mutation. Examination of the locations of these
amino acids in recently reported structures of the HIV-1
CA hexamer [9,10] revealed that R132 is positioned on
the surface of the CA molecule facing the NTD-NTD
interface (Figure 10A). E45 is in the vicinity of this
interface as well; however, the distance between these
two side chains prohibits a direct interact with one
another, making it unlikely that R132T directly offsets
the stability defect resulting from E45A. The R132T
substitution could act by restoring the overall net charge
of CA, which would be consistent with our previous
findings that the stability of the HIV-1 capsid is sensitive
to changes in ionic strength and pH [17]. Alternatively,
the E45A mutation might affect the network of water-
mediated hydrogen bonds observed at the NTD-NTD
interface in the X-ray crystal structure [10], with R132T
mutation partially restoring the H-bonding network. It
should be noted that the hexamer crystal structure was
determined with a mutant protein that contained two
amino acid substitutions, one of which was a Glu to Cys
change position 45.
Our results with the P38A/T216I mutant are reminis-
cent of another study of CA-NTD mutants in which a
second-site substitution at position 208 in the CTD
restored replication to mutants containing substitutions
at His62 in the NTD, which were associated with struc-
tural impairments in the capsid [42]. A recent cryoEM
structural model of the assembled capsid may help
explain how T216I, which resides in the C-terminal
domain of CA, modulates the effects of the P38A substi-
tution in the N-terminal domain. In the model, T216
resides at the CTD-CTD interhexamer interface. Substi-
tution of Cys at positions 207 and 216 resulted in inter-
subunit disulfide crosslinking within HIV-1 particles,
supporting the model [43]. Thus, the T216I substitution
may stabilize the CTD-CTD interhexamer interface,
thereby offsetting the structural effects of the P38A sub-
stitution. Moreover, T216 is also near the NTD-CTD
intersubunit interface in the hexamer (Figure 10B),
where it may also modulate the stability of the viral
capsid.
In our previous studies, we observed a strong depen-
dence of HIV-1 infection on the proper stability of the
viral capsid. Specifically, ten CA mutants exhibiting
altered capsid stability were impaired for infectivity,
while five other mutants with normal infectivity exhib-
ited capsid stability similar to the wild type [17]. This
begs the question: how do the CA suppressor mutations
rescue HIV-1 infectivity without restoring normal capsid
stability in vitro? While the simplest interpretation is
that capsid stability is irrelevant for infection, we think
this improbable because of the strong correlation we
previously observed. One possible alternative explana-
tion is that the biochemical assays we have employed
are limited in their ability to detect subtle changes in
capsid stability. HIV-1 capsid stability is altered by
changes in pH and ionic strength in vitro [17], and the
conditions in which uncoating takes place in target cells
are unknown. A second possibility, which we favor, is
that the suppressor mutations alter interactions with
host factors that participate in HIV-1 uncoating in tar-
get cells. Based on the current and previous in vitro and
cell-based studies, we propose that HIV-1 infection is
dependent on the proper HIV-1 capsid stability, but that
the effects of changes in intrinsic capsid stability can
also be mitigated by secondary mutations that alter
interactions with host cell molecules, or their conse-
quences. In support of this hypothesis, we have observed
that an HIV-1 CA mutant with five substitutions in CA,
remains infectious despite exhibiting a remarkably stable
capsid [33,44]. Furthermore, the observation that HIV-1
can escape requirement for expression of host factor
point mutations in CA confirms that CA exhibits func-
tional plasticity [45]. Additional studies of the determi-
nants of HIV-1 capsid stability and its interactions with
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host factors should lead to an improved understanding
of HIV-1 uncoating and facilitate the discovery and
development of pharmacologic inhibitors targeting this
critical stage of the virus life cycle.
Conclusions
We have identified second-site suppressors of mutations
that alter the stability of the viral capsid. The suppres-
sors restore the ability of the mutant viruses to replicate
in T cells, and revert the mutant phenotypes in several
cell-based functional assays. However, the biochemical
defects in capsid stability produced by the original
mutations were not corrected by the suppressor muta-
tions. We propose that proper uncoating in target cells
depends on the intrinsic stability of the capsid and on




293 T, HeLa-CD4/LTR-lacZ (Hela-P4) cells were cul-
tured in Dulbecco’s modified Eagle’s medium (Cellgro)
supplemented with 10% fetal bovine serum, penicillin
(50 IU/ml), and streptomycin (50 μg/ml) at 37°C and 5%
CO2. CEM cells were cultured in RPMI 1640 medium
with the same supplements. The wild-type HIV-1 pro-
viral DNA construct R9 [46], encoding full-length open
reading frames for all HIV-1 structural and accessory
genes, was used for these studies. R9 clones encoding
mutations E45A and P38A in CA were previously
described [47] and were the generous gift of Dr. Wes
Sundquist. HIV-GFP, an env-defective proviral clone
encoding GFP in place of nef [48], was used to generate
pseudotyped reporter particles. Viruses were produced
by calcium phosphate transfection of 293 T cells (20 μg
of plasmid DNA per 2 × 106 cells) as previously
described [49]. Five μg of pHCMV-G [50] were included
in the transfection mix for producing VSV-G-pseudo-
typed viruses with env-defective variants of the respec-
tive proviral clones. One day after transfection, culture
supernatants were harvested and clarified by passage
through 0.45-μm-pore-size filters, and aliquots were fro-
zen and stored at -80°C. The CA concentration of each
virus stock was quantified by p24 enzyme-linked
Figure 10 Locations of mutations in the structure of the CA hexamer. (A) Top and side views of a CA hexamer showing E45 (green) and
R132 (yellow) side chains from the NMR structure of CA151 (PDB ID: 3H47). (B) Same views, highlighting P38 and T216. P38 (red) in helix 2 is
located at the CA NTD-NTD interface and is adjacent to helix 3 in the adjacent subunit. T216 (blue) in helix 11 is near the CA NTD-CTD interface
and is close to helix 7 in the nearby subunit.
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immunosorbent assay (ELISA), as previously described
[51]. Reverse transcriptase activity was quantified in
viral stocks by polymerization of 3H-TTP, as previously
described [52].
HIV-1 replication assay
Viral replication was determined by inoculation of cul-
tures of CEM cells (2 × 105 cells in 0.2 ml) with quanti-
ties of virus corresponding to 2 ng of p24 antigen. Every
two days, samples of culture supernatants (100 μl) were
withdrawn and replaced with an equal volume of fresh
medium. Reverse transcriptase activity in culture super-
natants was quantified as previously described [53].
HIV-1 adaptation studies
Virus stocks, normalized for RT activity, were used to
inoculate CEM cell cultures. Culture supernatants were
harvested at peak of RT activity, and normalized quanti-
ties of viruses were re-inoculated in to new CEM cul-
tures. The mutant viruses emerged after approximately
one month of culture. Two additional passages of infec-
tion in fresh CEM cells were performed until accelerated
growth (emergence in 15-20 days) was observed. Cells
were harvested immediately following the peak of RT
activity from the third passage. Proviral DNA was puri-
fied with the DNeasy kit (Qiagen), and regions of Gag
were PCR amplified using pfu DNA polymerase (Strata-
gene) to a 800-bp BssHII-SpeI fragment spanning MA
and part of CA coding region and a 500-bp SpeI-ApaI
fragment spanning part of CA and NC coding region.
The BssHII-SpeI fragment was amplified using sense pri-
mer 5’-GGAGATCTCTCGACGCAG-3’ and anti-sense
primer 5’- TTTAATCCCAGGATTATCCAT-3’. The
SpeI-ApaI fragment was amplified using sense primer
5’-GCATGCAGGGCCTATTGC -3’ and anti-sense pri-
mer 5’- CCTGTCTCTCAGTACAATC-3’. Following
identification of additional mutations by DNA sequen-
cing of the PCR products, the corresponding SpeI-ApaI
fragments were transferred into R9.E45A or R9.P38A
proviral clones. The individual single R132T and T216I
mutants were constructed by transferring the mutant
SpeI-ApaI segments into the wild-type R9 plasmid.
Mutant viral constructs were verified by sequencing of
the corresponding regions.
Assay of HIV-1 infectivity
The HeLa-P4 cell line, a HeLa cell clone engineered to
express CD4 and an integrated long terminal repeat
(LTR)-lacZ reporter cassette [54], was used to quantify
HIV-1 infectivity, as previously described [53]. Infected
cells were identified by staining with X-gal, and the spe-
cific infectivity of each virus was defined as the number
of infected cells per ng of p24 antigen in the inoculum.
PF74 was synthesized by the Vanderbilt Institute of
Chemical Biology Synthesis Core, Vanderbilt University,
Nashville, TN 37212. Assays of PF74 inhibition were
performed with a fixed concentration of each virus, with
the inhibitor present at the indicated concentrations in
the inocula.
Assay of HIV-1 uncoating in vitro
The uncoating of purified HIV-1 cores was assayed as
described previously [17,55]. Purified cores were diluted
in STE buffer and incubated at 37°C. Following incuba-
tion, the particles were subjected to ultracentrifugation
to separate free CA from intact cores. Supernatants and
pellets were analyzed for CA content by ELISA to deter-
mine the percentage of total CA released from the cores
during the incubation.
Saturation-of-restriction assays
VSV-pseudotyped HIV-GFP reporter particles were
titrated onto FRhK-4 and OMK cell monolayers to
determine the appropriate dose for use in the assays.
The abrogation-of-restriction assay was performed as
previously described [34,40]. Cultures (20,000 cells per
well in 24-well plates) were inoculated with fixed (subsa-
turating) quantity of an HIV-GFP reporter virus
together with various concentrations of VSV-G-pseudo-
typed non-reporter viruses in the presence of polybrene
(8 μg/ml) in a total volume of 300 μl. One day later,
complete medium (1 ml) was added. Two days after
infection, cells were detached using trypsin and were
fixed by the addition of an equal volume of phosphate-
buffered saline containing 4% paraformaldehyde. Cellu-
lar GFP expression was quantified by flow cytometry by
using a FACSCalibur instrument (Becton Dickinson),
and the percentage of GFP-expressing cells was deter-
mined with Cellquest software. A minimum quantity of
5,000 cells was analyzed for each sample.
CA protein expression and purification
pET21a-based plasmids were constructed for full-length
CA protein expression in E. coli BL21-DE3. An NdeI-
XhoI fragment was amplified from WT and mutant CA
cDNA using sense primer 5’- GGAATCCCATATGCC-
TATAGTGCAGAACCTCCAGGGG-3’ and anti-sense
primer 5’- CCCCTCGAGTCACAAAACTCTTGCTT-
TATGGCCGGG-3’ and inserted into the NdeI-XhoI site
of pET21a and verified by DNA sequencing. CA pro-
teins were expressed and purified as previously
described [56], except where noted. Proteins were eluted
from a UnosphereQ (Bio-Rad) column at NaCl concen-
trations ranging from 70 to 90 mM. Most of the E45A
protein was present in the flow-through. The protein
solutions were dialyzed into 50 mM sodium phosphate
buffer, pH 8.0, concentrated with Centriprep centrifugal
filters (Millipore) to a concentration of ~300-500 μM
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and stored frozen at -80°C until needed. The proteins
were > 99% pure by SDS-PAGE.
To produce isotopically-labeled CA proteins for NMR
studies, cells were grown in modified minimal medium
at 23°C using 15NH4Cl and/or
13 C glucose as a sole
nitrogen and carbon source in E. coli Rosetta 2 (DE3)
and induced for 16 h with 0.4 mM IPTG. Soluble CA-
NTD proteins were obtained by sonication in lysis buf-
fer containing 25 mM sodium phosphate, pH 7.0, 1 mM
DTT, and 0.02% sodium azide followed by ultracentrifu-
gation at 127,000 × g. Proteins were purified by using 10
mL Hi-Trap QP (GE Healthcare, Piscataway, NJ) at pH
7.0 and pH 8.5 with 1 M NaCl gradient. The fractions
containing CA-NTD were further purified using Hi-
Load Superdex75 26/60 (GE Healthcare, Piscataway, NJ)
equilibrated with 25 mM sodium phosphate, pH 6.5,
100 mM NaCl, 1 mM DTT, and 0.02% sodium azide.
The molecular mass of each CA-NTD protein was con-
firmed by LC-ESI-TOF mass spectrometry (Bruker Dal-
tonics, Billerica, MA) and isotope labeling efficiency was
estimated to be greater than 99%.
Assays of CA assembly in vitro
Purified full-length CA proteins were assembled by
rapid dilution into concentrated NaCl solutions at 23°C
to yield a final concentration of 2.25 M NaCl and pro-
tein of 50 μM, and the course of the reaction was moni-
tored by turbidity. For kinetic analysis, the reaction was
rapidly mixed and placed into a 1-mm quartz cuvette.
Approximately 20 s elapsed between the time of the
addition of salt and the first time point measured. The
increase in optical density was monitored at 350 nm for
30 min as previously described [31].
NMR analysis
Experiments were conducted at 25°C on U-[15 N,13 C]-
or U-[15 N]-labeled CA-NTD samples in NMR buffer
(25 mM sodium phosphate buffer, pH 6.5, 100 mM
NaCl, 2 mM DTT, and 0.02% sodium azide) using Bru-
ker Avance 700 and 600 MHz spectrometers, equipped
with 5 mm, triple resonance and z-axis gradient cryop-
robes. Complete backbone assignments of the wild-type
CA-NTD were obtained using 3D HNCACB and HN
(CO)CACB experiments on U-[13 C,15 N]-labeled pro-
teins. Complete assignments of the 2D 1H-15 N HSQC
spectra for the E45A, R132T and E45A/R132T mutant
proteins were obtained unambiguously by direct com-
parison with the spectrum of wild-type protein since the
spectra of the mutants are essentially identical to that of
wild-type, except for few resonances arising from amino
acids around the mutation sites. The assignment of the
P38A mutant spectra were less straightforward since
more (~ 20) resonances exhibited changes > 0.1 ppm
from the wild type. Nevertheless, all but two resonances
(Trp23 and Met55) were unambiguously assigned.
Structural perturbations created by the mutations were
assessed by evaluating the combined amide chemical







with ΔδHN and ΔδN representing the
1HN and 15 N
chemical shift differences, respectively.
Cell cycle arrest
To generate cell cycle-arrested target cells for infectivity
assay, HeLa-P4 cells (4 × 104 cells/well) were plated in
48-well plates. Aphidicolin (Sigma-Aldrich) was added
to a final concentration of 2 μg/ml upon seeding
[25,57]. The next day, cells were inoculated with viruses
overnight; aphidicolin was also present during this per-
iod. Cultures were replenished with 0.5 ml fresh media
and cultured for another 24 hours prior to X-gal stain-
ing to reveal infected cells.
Assays of HIV-1 proviral DNA in target cells
HIV-1 stocks were treated with DNaseI, and quantities
corresponding to 100 ng p24 were used to inoculate cul-
tures of HeLa-P4 cells (100,000) in triplicate, in the pre-
sence or absence of the reverse transcriptase inhibitor
Efavirenz (1 μM). Total DNA was harvested at 8 hours
post-inoculation and was purified using the DNeasy kit
(Qiagen). DNA was eluted in 100 μl of water. Five
microliter aliquots were assayed for 2nd-strand transfer
reverse transcription products by quantitative PCR, as
previously described [17].
Structural representation
Molecular graphics images in Figure 6 were produced
with MOLMOL [58], and those in Figure 9 were pro-
duced using the UCSF Chimera package from the
Resource for Biocomputing, Visualization, and Infor-
matics at the University of California, San Francisco
(supported by NIH P41 RR-01081)[59]. The images are
based on the 1.9A resolution structure of the CA hex-
amer (Protein Data Bank entry 3H47.pdb)[10].
Additional material
Additional file 1: Figure showing monitoring of structural
perturbations of CA-NTD caused by mutations with 1H-15 N HSQC
NMR. Superimposed 1H-15 N HSQC spectra of 15 N-labeled wild-type
(black) and mutants (red), E45A (A), P38A (B), E45A/R132T (C) and R132T
(D). The peaks showing substantial perturbation due to the mutation are
labeled with assignments.
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